Revvity Slashes Outlook As China Policy Deals Diagnostics Blow

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025.

The Massachusetts-based company announced second-quarter sales of $720.28 million, an increase from $691.69 million reported a year ago, surpassing the consensus estimate of $710.71 million.

Delving into the financials, the company’s adjusted earnings for the second quarter were $1.18, exceeding the consensus of $1.14. However, adjusted operating income decreased to $192 million from $199 million in the same period last year, and the adjusted operating profit margin also saw a decline to 26.6% compared to 28.8% a year ago.

Also Read: Why Thermo Fischer Stock Is Rising Wednesday

The company's life sciences segment saw revenue increase by 5% (+4% organically) to $366 million, led by approximately 30% growth in the Signals Software franchise.

Diagnostics sales increased 3% year-over-year to ...